-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

D is for Diagnosis: Detecting and Treating Rare Disorders in Hematologic Practice

Sponsor: Sanofi Genzyme
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Anemias, Diseases, Therapies, Combinations, Hemoglobinopathies, Immune Disorders
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Atul Mehta, FRCP, Royal Free Hospital
Disclosures:
Mehta: Biomarin: Membership on an entity's Board of Directors or advisory committees, Research Funding; Protalix/Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amicus: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda/Shire: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi Genzyme: Membership on an entity's Board of Directors or advisory committees, Research Funding.
Speakers:
Marie Scully, MD, University College London Hospitals, Cardiometabolic Program, National Institute for Health Research UCLH/UCL Biomedical Research Centre , Adrian Newland, MD, Queen Mary University of London and D. Mark Layton, MD, Imperial College of London
Disclosures:
Scully: Alexion: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Takeda: Speakers Bureau; Ablynx/Sanofi: Consultancy, Other: Advisory Board, Speakers Bureau; Shire/Takeda: Other: Advisory Board, Research Funding, Speakers Bureau; Novartis: Other: Advisory Board, Speakers Bureau; Sanofi: Consultancy, Speakers Bureau. Newland: Amgen: Other: Ad Board, Research Funding, Speakers Bureau; GSK: Research Funding; Novartis: Other: Ad Board, Research Funding, Speakers Bureau; argenx: Other: Ad Board; Dova Pharmaeceuticals: Other: Ad Board; Grifols: Other: Ad Board; Sobi: Other: Ad Board.
This program will discuss the latest data, share perspectives and best practices, and forecast applications of key clinical challenges and questions regarding identification of rare hematologic disorders and the importance of differential diagnosis when treating patients who present with hematologic symptoms of unknown origin. Attendees will be challenged to play the role of the detective as they approach each patient case to ultimately uncover the underlying disease at play. Audience members will be encouraged to look for ‘clues’ as they diagnose each patient, similar to how a detective would solve a case.  After solving each case, the faculty will present a comprehensive overview of available treatment options for each rare disease. The program is designed to take an investigational approach to treating rare hematologic diseases and will encourage interaction between faculty and audience.
See more of: Satellite Symposia